Skip to content

Public FDA record

Z-0083-2022: cobas EGFR Mutation Test v2-Somatic gene mutation detection system Catalog Number :07248563190

Recall record Z-0083-2022 for Roche Molecular Systems, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0083-2022
Company in FDA record
Roche Molecular Systems, Inc.
FDA record creation date
Oct 8, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

False Mutation Detected results for the exon 20 insertion (Ex20Ins) mutation when using the cobas EGFR Mutation Test v2, may lead to inappropriate treatment

Source facts

Action
Roche issued Urgent Medical Device Correction letter on 9/3/21 via UPS Ground. Letter states reason for recall, health risk and action to take: Follow the cobas DNA Sample Preparation Kit (catalog number 05985536190) IFU for sample input with regard to the number of FFPET sections and DNA concentration. Follow the cobas cfDNA Sample Preparation Kit (catalog number 07247737190) IFU for plasma samples. " If an Ex20Ins Mutation Detected result is generated with the cobas EGFR Mutation Test v2, you must confirm the result with another method (e.g., sequencing or other PCR-based tests). " Consider reviewing results generated since May 2021. Amivantamab was approved by the U.S. Food and Drug Administration (FDA) for NSCLC patients with EGFR Ex20Ins on May 21, 2021. Test result reports with Ex20Ins Mutation Detected may be considered for confirmatory testing using sequencing or other PCR-based tests, upon the discretion of a CAP/CLIA laboratory director. " Consult with your facility physician and/or pathologist to determine any clinical implications specific to your patients. " Complete all sections of the enclosed faxback form (TP-01381) and fax it to 1-855-208-4038 or email it to Roche8166@sedgwick.com. " File this UMDC for future reference. Please contact the Roche Support Network Customer Support Center, 24 hours a day, seven days a week at 1-800-526-1247 if you have questions about the information contained in this UMDC
Initiated
2021-09-03
Root cause
Under Investigation by firm
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Canada, UK, Poland, Spain, Italy, Sweden, Greece, Denmark, Norway, Netherlands, France, Czech Republic, Belgium, Austria, Slovakia, Hungary, Switzerland, Lithuania, Slovenia. Serbia, North Macedonia, Myanmar, Lebanon, Russia, Croatia, Morocco, Kazakhstan, Dominican Republic, Israel, El Salvador, Vietnam, Malaysia, Taiwan, China, Japan, Hong Kong, Korea, Brazil, Philippines, Thailand, Chile, Colombia, Singapore, Argentina, Australia, India, Uruguay, Ecuador, Panama, Costa Rica, Pakistan, Peru, Indonesia, New Zealand.
Recall number
Z-0083-2022
Recall status
Open, Classified
CDRH record ID
189083
FDA record created
2021-10-08
Recall event number
88607

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗